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Abstract
Background: As more men survive a diagnosis of prostate cancer, alternative models of follow-up care that address
men’s enduring unmet needs and are economical to deliver are needed. This paper describes the protocol for an
ongoing evaluation of a nurse-led supported self-management and remote surveillance programme implemented
within the secondary care setting.
Methods/design: The evaluation is taking place within a real clinical setting, comparing the outcomes of men
enrolled in the Programme with the outcomes of a pre-service change cohort of men, using a repeated measures
design. Men are followed up at four and 8 months post recruitment on a number of outcomes, including quality of
life, unmet need, psychological wellbeing and activation for self-management. An embedded health economic analysis
and qualitative evaluation of implementation processes are being undertaken.
Discussion: The evaluation will provide important information regarding the effectiveness, cost effectiveness and
implementation of an integrated supported self-management follow-up care pathway within secondary care.
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Background
The number of people surviving after a diagnosis of can-
cer has increased dramatically in recent years, and is
continuing to rise [1, 2]. For prostate cancer, an illustra-
tion of the 10 year survival rate is 84% in England and
Wales [3] and 98% in the United States [4]. Cancer
survivors are often left with challenging symptoms and
side effects of treatment and with psychosocial concerns
[5, 6]; specifically, prostate cancer survivors experience a
range of physical symptoms, psychological and emo-
tional difficulties and issues related to sexual function,
such as impotence [7].This is presenting challenges for
health care systems, in providing suitable follow-up care
for those who have completed treatment [5, 8], and
there is a need for more sustainable models of follow-up
care which deal with capacity issues but also better ad-
dress men’s survivorship needs.
In recent decades, a range of alternative follow-up care
delivery models have been explored, including nurse led
care, general/family practitioner led care, shared care,
and patient initiated care [9]. Evidence suggests that
these models are equivalent to the traditional clinic
model in detection of recurrence and patient satisfaction
[9]. In addition, a variety of psychosocial interventions
have been developed to address men’s unmet survivor-
ship needs, which appear to show some benefit for the
men involved [10–12].
Within the last decade there has been recognition of the
value of a self -management approach for cancer survivors
[13]. In the United Kingdom (UK), the National Cancer
Survivorship Initiative (NCSI) has promulgated an inte-
grated, risk stratified and individualised model of cancer
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survivorship care, involving supported self-management
and remote monitoring for the large proportion of cancer
survivors who are at low risk of recurrence [14]. Such a
model has recently been recommended for implementa-
tion in England by 2020, although a detailed model for
prostate cancer remains to be developed and tested [15].
There is recognition of the international relevance of the
principles of the model and its influence on programmes
of care internationally [8].
Within this context a service improvement initiative,
the TrueNTH Supported Self-Management and Follow-
up Care programme (described henceforth as the
Programme), has been funded in the United Kingdom
by the Movember Foundation, in partnership with
Prostate Cancer UK. The aim of the Programme is to
implement a sustainable model of follow-up care within
secondary care, based on the principles of risk stratifi-
cation, supported self-management (SSM) and remote
surveillance, to provide person-centred care through
which to address men’s survivorship needs. The imple-
mentation of the Programme is accompanied by a com-
prehensive evaluation to assess effectiveness, cost
effectiveness and implementation. This paper docu-
ments the evaluation protocol.
The Programme
The Programme delivers personalised survivorship care
through assessment of need, enhancement of men’s
knowledge, skills and confidence to self-manage and
easy access to advice and support. A stratified pathway
approach [14] is employed, recognising that a proportion
of post-treatment patients will be suitable for SSM.
The Programme was designed by a multi-disciplinary
team, including urology health care professionals, ex-
perts in self-management techniques, and survivors of
prostate cancer. The design team drew on previous work
on the redesign of cancer follow-up care [14, 16] as well
as the broad cancer survivorship and self-management
literature. Urology and oncology teams at two National
Health Service (NHS) Trusts were involved in the devel-
opment of the clinical criteria used to judge suitability of
men for the Programme and in piloting the Programme
to assess feasibility and acceptability for both men and
the clinical team.
Figure 1 details the components of the Programme
and its underlying principles. The Programme is initially
aimed at men being treated with radical prostatectomy,
radiotherapy, or primary androgen deprivation therapy
(PADT). Men are assessed for suitability at a post
treatment clinic appointment with their consultant or
Clinical Nurse Specialist (CNS), using clinical criteria
including specified prostate specific antigen (PSA)
levels for each treatment type, together with clinician
assessment and discussion with the patient that they
are functionally and emotionally suitable for SSM and
remote surveillance. Men are first assessed for suit-
ability from 6 weeks post radical prostatectomy and
radiotherapy, or 3 months post commencement of
PADT.
If a man is suitable for the Programme, this will be
their last clinic appointment. Henceforth, they are moni-
tored remotely by the specialist team, with a system of
rapid re-access to clinic if indicated. There is the
addition of a Support Worker role to the team, who is
the mainstay of programme delivery, acting as coordin-
ator of a man’s post treatment care and first point of
contact for men who have queries or concerns, facilitat-
ing referrals to health and community resources. Men
meet with the Support Worker at this point and are in-
troduced to the Programme.
Soon after their entry into the Programme (ideally
within 6 weeks), men attend a 4 h Supported Self-
Management workshop, to prepare them for self-
management and remote monitoring of their prostate
cancer follow-up care, with a focus on living well after
cancer treatment, promoting healthy lifestyles and setting
personal health and wellbeing goals. Men complete a
holistic needs assessment (HNA) during the session. Each
workshop usually comprises between eight and 10 men
and is facilitated by the CNS and Support Worker, who
have been trained in workshop delivery skills and fol-
low a facilitator manual. The workshops are based on
principles of andragogy [17], Bandura’s social learning
theory [18] and Adair’s action-centred leadership
model [19].
The Support Worker initiates a follow-up telephone
consultation after the workshop, to check that the man
has grasped the main points put forward in the work-
shop and to answer any questions. A care plan is drawn
up if appropriate. Contact with the man beyond this
initial telephone call is negotiated individually, with the
expectation that some men will need more contact and
support for self-management than others.
Self-management and remote monitoring are facili-
tated by a bespoke Patient Online Service, which has
both patient and health care professional facing func-
tions. Men can access personal information such as
treatment summaries and care plans, as well as validated
sources of information to support self-management.
They can submit their HNA and can have a two way
conversation with a member of their clinical team via a
secure system. The system prompts men when blood
tests are due and men can see their PSA test results
promptly. The health care team run virtual clinics
through an electronic PSA tracking system which is
interfaced with the Patient Online Service, reviewing
PSA test results and HNAs, re-calling to clinic a man
who has any indicators for concern.
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Methods/design
Setting
The service re-design is being evaluated in four prostate
cancer treatment centres within the NHS in England.
Three sites were selected following an expression of
interest process. Criteria for selection included enthusi-
asm of the clinical team, capability of IT departments to
implement the proposed IT solution, and inclusion of
hospitals in both urban and rural locations. The fourth
site had previously been involved in development of the
clinical criteria and piloting work, and was added as an
evaluation site after 5 months of recruitment in order to
boost numbers.
Design
A mixed methods design is being implemented to assess
the value of the Programme and to understand processes
of implementation. The evaluation aims to: 1) assess the
effectiveness of the Programme across key outcomes 2)
assess the impact of the Programme on costs 3) assess
the process of implementing the Programme, in order to
identify any facilitating and inhibiting factors.
Evaluation of effectiveness
Design The effects of the Programme on patient
outcomes are being assessed by comparing the out-
comes of men enrolled in the Programme with the
outcomes of a pre-service change cohort of men,
using a repeated measures design. The evaluation
takes a pragmatic approach, testing the effectiveness
of the Programme in a real clinical setting, allowing
for clinical judgement in assessing men’s suitability
for the new service and for flexibility in service de-
livery [20].
Comparator group The comparator group is a pre-
service change group of men, recruited from the cohort
of men in prostate cancer follow-up care at the four sites
during the period immediately prior to the introduction
of the Programme. The comparator group men receive
their hospital’s standard follow-up care (standard care)
as it was before the service change; this is either clinic
based follow up with a urological surgeon, oncologist or
CNS, or telephone follow up with a CNS.
Where capacity allows, men in the comparator group
are migrated to the new service once they have com-
pleted their final study questionnaire.
Eligibility Men are eligible to enter the evaluation if
they are: i) within 3 years of completion of radical pros-
tatectomy/radiotherapy or within 3 years of commence-
ment of PADT ii) are 18 years of age or older and iii)
have adequate English language ability to complete study
questionnaires. Men who are unable to give informed
consent and men participating in clinical trials which re-
quire face-to-face contact are excluded.
Fig. 1 Components of the programme and underlying principles
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Data collection Data are collected by postal question-
naire at recruitment (T0), then 4 months (T1) and 8
months post-recruitment (T2) (see Fig. 2). Clinical and
treatment data (cancer stage, grade, date of diagnosis,
and treatment received) are collected from medical re-
cords. If a participant dies during their involvement with
the study, it is ascertained whether the death was due to
prostate cancer.
Recruitment Men were recruited to the comparator
group between September 2014 and June 2015, and to
the Programme group between April 2015 and February
2016, with data collection completed in December 2016.
Men attending a clinic appointment who met the eligi-
bility criteria for the evaluation were initially approached
by clinical staff or a research nurse, to introduce the
evaluation and to ask for consent for their contact de-
tails to be passed to the research team. Men who con-
sented to contact were sent, by post, an introductory
letter, a patient information sheet, consent form, baseline
questionnaire and a freepost envelope for return of the
completed documents.
Outcome measures The evaluation is comparing the
Programme with standard care across a number of
different outcomes; a series of validated patient reported
outcome measures are being used (see Table 1), to re-
flect multiple outcomes of interest relevant to the
theoretical model underpinning the Programme [21].
Measures of general health status, physical symptoms,
cancer specific quality of life, unmet needs, psychological
wellbeing, worry about cancer recurrence, activation for
self-management, and general health behaviours are be-
ing collected at T0, T1 and T2 time points. In addition,
questions about health service use and satisfaction with
follow-up care are included in the T1 and T2 question-
naires. Socio-demographic characteristics are also collected.
The primary outcome is unmet need, measured with using
the Cancer Survivors Unmet Needs measure [22].
Sample size calculation The sample size was calculated
to achieve at least 90% power in two sided tests for vari-
ables which achieve a moderate intervention effect (0.3
or larger). This would require a sample of 235 partici-
pants per group and we therefore aimed to recruit
around 300 men to each arm of the study, allowing for
20% being lost to follow-up by the 8 month assessment.
Data analysis Data analysis will follow a pre-specified
data analysis plan. Analyses will be conducted on an
‘intention to treat’ basis. We will first describe the base-
line characteristics of participants at time T0 within each
group and will compare clinical and demographic char-
acteristics and outcome measure scores of the two
groups. The same comparisons will be made with base-
line data between those continuing to four and 8 month
follow-up and those lost to attrition.
A regression analysis will be conducted for each of the
outcome measures at the 4 month and 8 month time
points separately, controlling for study site, the outcome
in question if available at T0, and baseline co-variates in-
cluding age, type of treatment, educational attainment,
time since diagnosis, domestic status, co-morbidity, em-
ployment status, and ethnic status. If other factors differ
between groups at baseline, additional controlled ana-
lyses will be carried out.
We will also estimate a mixed model including out-
come at four and 8 months simultaneously, including an
Fig. 2 Study flow
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interaction to give separate estimates of the Programme
versus standard care comparison at each follow-up
point.
Finally, we will investigate whether there are any dis-
tinct subgroups for whom the intervention is effective.
Guided by existing literature to indicate likely subgroup
effects, separate regression analyses will be conducted
for older versus younger men, men with and without co-
morbidities, and men with higher and lower levels of
deprivation. We will address subgroup analyses within
the context of regression modelling (either linear or
logistic). Interaction terms between each specified di-
chotomous factor (indicating subgroups) and the
Programme versus standard care factor will be exam-
ined. Where interaction terms achieve statistical sig-
nificance (at the 5% level), we will examine separate
Programme versus comparator group estimates for
each subgroup. All subgroups analyses will be considered
exploratory in nature.
Economic evaluation
Design The economic evaluation will compare costs
and health outcomes of men in the Programme and the
comparator group of men in standard care. The primary
analysis will be from a health service perspective, with a
secondary analysis from the patient perspective. A cost-
consequence analysis will be conducted using the full
range of outcome measures.
Data collection Costs of the workshop and the Patient
Online System will be sourced from providers. The IT
costs will be annuitized over a plausible useful lifespan
assuming optimal utilisation to provide a realistic cost
per patient. The nurse time for monitoring and follow
up using the surveillance system will be sourced from
observation of a small sample of the staff performing the
activity in situ. This resource use will be priced using
unit costs based on national tariffs [23] or from site fi-
nance managers.
Self-reported service use data is collected in the four
and 8 month questionnaires. This captures health, social
and voluntary service use, including contacts with the
General Practitioner, Practice Nurse, District Nurse, so-
cial worker, physiotherapist, dietician, psychologist, com-
plementary therapies, outpatient appointments, and
hospital stays. Data on routine clinic appointments and
telephone contact with the urology team will be sought
from site staff. Service use will be costed using national
tariffs [23]. All participants will also be asked to report
out-of-pocket expenses on travel to any appointments
and on prostate cancer related care products and medi-
cations, and any time spent by informal carers in sup-
porting the patient. The primary outcome measure for
the economic evaluation is the EQ-5D-5 L [24] collected
at all three data collection points.
Analysis The average cost per patient will be calcu-
lated for both Programme and comparator groups. For
the Programme group, this will comprise the work-
shop, the Patient Online System and associated nurse
time, and the costs of all health and social care. The
costs for the comparator group will comprise the cost
of standard care and all other health and social care.
The individual EQ-5D-5 L survey results will be used
to estimate patient utility at each time point. These
will be integrated over the 8 month follow up using
the area under the curve method to calculate accrued
quality-adjusted life years (QALYs) for each partici-
pant. Average QALY differences between groups will
be estimated using ordinary least squares regression,
controlling for differences in baseline utility. White ad-
justed standard errors will be used to account for un-
observed heterogeneity.
The total cost per patient and total QALYs per patient
will be compared between the Programme and compara-
tor groups using the incremental cost effectiveness ratio
(ICER). Uncertainty will be handled non-parametrically
using bootstrap resampling with replacement [25]. De-
terministic sensitivity analysis will be conducted around
main drivers of cost, and to allow for specific uncertain-
ties around estimated unit costs. Exploratory multivari-
ate regression analysis will be employed to assess the
relationship between health and cost outcomes and
other sociodemographic data. The cost consequences
analysis will compare the two service delivery models
across the full range of outcomes.
Assessing implementation
Design The aim of this component of the evaluation is
to assess the process of implementation of the
Programme and to identify any barriers and facilitators
to implementation. Data are being collected though
semi-structured interviews with staff involved in service
delivery or management, and with a subsample of men
taking part in the questionnaire study. Normalisation
Process Theory (NPT) [26] is being used to sensitise the
interviews to factors which may help or hinder the em-
bedding of the Programme at the sites.
Data collection Semi-structured interviews are com-
pleted with a sample of up to 10 staff from each of
the four study sites. Both clinical and managerial staff
involved with the Programme were identified through
discussion with the lead clinician and lead nurse at
each site. These interviews are conducted by tele-
phone and focus on experiences of implementing the
Programme.
Frankland et al. BMC Cancer  (2017) 17:656 Page 7 of 10
Similarly, interviews are being conducted with a
maximum of 12 men from each of the four study sites,
to include men who have experienced standard care
(maximum of four men per site) and men enrolled in
the Programme (maximum of eight men per site). The
interview guides for both patients and staff are provided
in Additional file 1. Men were purposively selected from
those who indicated on their baseline questionnaire that
they were happy to be contacted regarding an interview.
The sample was selected to take account of age, type of
cancer treatment, time since diagnosis and computer
usage. The interviews focus on men’s experience of
follow-up care and the post treatment period, and take
place by telephone or face-to-face according to
preference.
Analysis Each audio-recording is transcribed verbatim
and is checked against the recording. The analysis is
taking a team approach. The initial coding frame was
developed through a process of independent coding and
subsequent discussion of a number of transcripts by at
least two of the study team. The development of codes
took both a deductive and inductive approach, having an
initial focus on the research question, NPT constructs
and the underlying theory of change, but also being open
to codes that emerge from the data. The reliability of the
individual coders was established over a number of tran-
scripts and then the coding frame will be applied to
remaining transcripts. Analysis will involve the constant
comparison of data and close attention to deviant cases.
Regular evaluation team meetings will be held to reach
consensus on themes and findings.
Ethics and reporting The study received ethical approval
from the National Research Ethics Service, East of
England – Cambridge South (reference number 11/EE/
1021), research governance approval from the individual
NHS Trusts involved with the study, and has been
adopted by the National Institute of Health Research Clin-
ical Research Network (ID 17238). Study reporting will
follow appropriate guidelines [27–29].
Discussion
The TrueNTH Supported Self-Management and Follow-
up care Programme implements an integrated supported
self-management and remote monitoring model of
follow-up care within secondary care. The Programme
aims to address contemporary problems with clinic cap-
acity, but also to offer men a more tailored follow-up
care experience that addresses their individual needs.
While other alternatives to the clinic based model of
post treatment care continue to be tested (for example,
[30–32]), this Programme offers an alternative which
maintains specialist oversight and input.
The Programme was funded as a service improvement
initiative with accompanying evaluation. The evaluation
takes a pragmatic approach [20], seeking to answer
questions about effectiveness of the model within an
everyday clinical setting, and also to provide information
on the practicalities of implementing and sustaining
such a model. Such information should provide relevant
and useable conclusions for local decision makers
considering implementation of a similar model in their
setting [20].
There are a number of limitations to the study design.
First, the use of a non-randomised comparator group
represents a reduction in the ability of the study to attri-
bute outcomes to the Programme, though the inclusion
of a baseline measurement helps to address this issue,
allowing for statistical adjustment of known confounders
[33]. Second, men will be followed up for a period of 8
months, meaning that the study will only be able to
comment on outcomes over this time period and not
over a longer term [21].
Within the context of the rising number of cancer
survivors, alternatives to resource intensive, medically
focussed models of follow-up care are required, and sup-
ported self-management has been suggested as beneficial
for cancer survivors with stable disease [34]. This evalu-
ation of a supported self-management programme for
men with prostate cancer will provide useful information
for management of this particular group, but will also
add to the literature on alternatives to clinic based
follow-up care which will be of relevance to other
groups of cancer survivors across the globe.
Additional file
Additional file 1: Interview guides for patient and staff interviews.
(DOCX 37 kb)
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